Medical University of South Carolina and Flatiron Health Announce Collaboration
Collaboration brings Flatiron’s oncology-specific decision support platform to oncology care clinicians at MUSC Hollings Cancer Center.
Flatiron Health has announced a collaboration with the Medical University of South Carolina (MUSC), bringing its oncology support platform to care clinicians at MUSC Hollings Cancer Center, according to a press release.1
Flatiron Assist, Flatiron’s oncology-specific clinical decision support platform, prioritizes evidence-based medicine, site-preferred pathways, and clinical research at the point of care. Through integration with Epic’s electronic health record at MUSC, Flatiron Assist will determine and promote site-preferred pathways and open clinical trials alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
“Partnering with the Medical University of South Carolina’s Hollings Cancer Center, a market-leading cancer care provider, is an incredible opportunity to accelerate our shared vision for the delivery of more standardized, efficient, and effective cancer care.” said James Hamrick, MD, vice president of clinical oncology at Flatiron Health in the press release. “Flatiron Assist, tailor made for oncology, offers a clinical decision support platform that places emphasis on the latest evidence based medicine, aiming to reduce care variation while increasing access to clinical trials and novel therapies, ensuring patients at MUSC and beyond receive the highest quality of care.”
“MUSC Hollings Cancer Center is excited to partner with Flatiron Health on the development of cancer clinical pathways,” said Craig Lockhart, MD, MHS, director of the division of hematology and oncology and associate director of clinical science at the MUSC Hollings Cancer Center in the press release. “This project will reduce variability in cancer treatment while increasing the quality of cancer care provided across the state of South Carolina.”
Reference
1. The Medical University of South Carolina and Flatiron Health announce collaboration to drive more standardized, efficient, and effective cancer care. News release. March 13, 2024. Accessed March 14, 2024. https://flatiron.com/resources/the-medical-university-of-south-carolina-and-flatiron-health-announce-collaboration-to-drive-more-standardized-efficient-and-effective-cancer-care
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
